CHRS Stock Risk & Deep Value Analysis
Coherus Oncology Inc
DVR Score
out of 10
What You Need to Know About CHRS Stock
We analyzed Coherus Oncology Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CHRS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
CHRS Risk Analysis & Red Flags
What Could Go Wrong
Despite significantly improving its balance sheet and securing a strong cash position, Coherus continues to incur substantial net losses of over $50M per quarter. If LOQTORZI's commercial growth slows considerably or if key pipeline readouts in 2026 are negative, the company's cash reserves could deplete faster than anticipated, forcing another potentially dilutive capital raise at an unfavorable valuation.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
Medium
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Q1 2026 EPS missed consensus and net loss widened YoY, despite revenue growth, indicating ongoing high operational costs.
- ⚠
High cash burn rate with negative operating cash flow (implied by net losses) requires continued external funding or dramatic LOQTORZI ramp-up.
- ⚠
Lack of analyst coverage and institutional sentiment data suggests lower visibility and potential for significant volatility.
- ⚠
Discrepancy in provided data: Shares Outstanding (2.30M) conflicts with Market Cap ($250.32M) and Current Price ($1.7), creating confusion for per-share metrics.
Upcoming Risk Events
- 📅
Slower-than-expected LOQTORZI commercial traction
- 📅
Negative or inconclusive clinical trial results for pipeline assets in 2026
- 📅
Increased competition in the NPC market or broader oncology space
- 📅
Higher-than-anticipated cash burn leading to earlier need for financing
When to Reconsider
- 🚪
LOQTORZI quarterly revenue growth significantly decelerates or declines for two consecutive quarters.
- 🚪
Cash and marketable securities fall below $75M without a clear, non-dilutive financing plan.
- 🚪
Phase 2/3 clinical trial failures for tagmokitug or casdozokitug.
- 🚪
Debt-to-equity ratio increases significantly above 100%.
Unlock CHRS Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Coherus Oncology is a high-risk, high-reward opportunity in targeted oncology. Its successful pivot is validated by LOQTORZI's rapid revenue growth and first-in-class position in NPC. Critically, the company has strategically de-risked its financial position via significant debt reduction and a substantial cash infusion, providing a runway to execute on multiple 2026 clinical catalysts for its pipeline. This improved financial stability and accelerating commercial execution lay the groundwork for potential multi-bagger returns if pipeline successes materialize and LOQTORZI achieves market leadership.
Is CHRS Stock Undervalued?
Unlock the full AI analysis for CHRS
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
CHRS Price Targets & Strategy
12-Month Target
$5.00
Bull Case
$10.00
Bear Case
$0.80
Valuation Basis
Based on 9x forward P/S multiple applied to projected $80M FY26 revenue, divided by ~147M shares outstanding (implied by market cap and current price, given data inconsistency).
Entry Strategy
Dollar-cost average between $1.50-$2.00, targeting dips towards recent support levels around $1.50.
Exit Strategy
Take initial profits at $5.00, reassess at $8.00-$10.00. Implement a stop loss if the price breaks below $1.20 (critical psychological support and previous lows).
Portfolio Allocation
5% for aggressive risk tolerance
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is CHRS Financially Healthy?
Valuation
P/E Ratio
-1.40
Forward P/E
3.24
Price/Book
2.80
Price/Sales
5.90
Profitability
Gross Margin
67.24%
Net Margin
-434.23%
Return on Equity
-860.29%
Revenue Growth
59.70%
EPS
$-1.22
Balance Sheet
Current Ratio
1.47
Quick Ratio
1.45
Debt/Equity
0.61
Total Debt
$38.80M
Cash & Equivalents
$172.10M
Other
Beta (Volatility)
1.03
Does CHRS Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The moat, primarily derived from LOQTORZI's first-in-class status and strong clinical data in NPC, is expanding with commercial adoption and pipeline progress. Its durability will depend on continued differentiation, success in broader indications, and ability to fend off potential new entrants or biosimilars in the long term, particularly after patent expiry.
Moat Erosion Risks
- •Emergence of superior or more cost-effective therapies for NPC from larger competitors.
- •Clinical trial failures for pipeline assets, limiting expansion of product portfolio and IP.
- •Market access challenges or reimbursement pressures for LOQTORZI.
- •Patent challenges or eventual expiry of LOQTORZI's exclusivity.
CHRS Competitive Moat Analysis
Sign up to see competitive advantages
CHRS Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (No specific data provided, but high-risk biotech can attract speculative retail interest if catalysts hit)
Institutional Sentiment
Neutral (No analyst consensus, price targets, or recent upgrade/downgrade information available in search results)
Insider Activity (Form 4)
No Form 4 filings or insider trading activity disclosed in search results for the last 90 days.
Options Flow
Normal options activity (No specific data available)
Earnings Intelligence
Next Earnings
2026-04-30
Surprise Probability
Medium
Historical Earnings Pattern
Q1 2026 EPS missed consensus by $0.03, suggesting a mixed reaction depending on underlying metrics.
Key Metrics to Watch
Competitive Position
Top Competitor
Not explicitly stated, but major oncology players like Merck (MRK) or Bristol Myers Squibb (BMY) in the PD-1/L1 space for broader context, although LOQTORZI has first-in-class status for NPC.
Market Share Trend
Gaining (LOQTORZI is 'first-in-class' in an underserved niche, implying market capture potential)
Valuation vs Peers
Trading at 5.93x P/S, which can be considered reasonable for a high-growth oncology biotech given its first-in-class product and pipeline potential, but would be high for a mature, profitable peer. Valuation is speculative given lack of profitability.
Competitive Advantages
- •First-in-class FDA approved therapy (LOQTORZI) for nasopharyngeal carcinoma (NPC)
- •Strong 6-year overall survival data for LOQTORZI (Phase 3 JUPITER-02 trial)
- •Strategic focus and capital allocation towards proprietary oncology pipeline
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive CHRS Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings on April 30, 2026 (focus on LOQTORZI sales and cash burn)
- •Continued commercial ramp-up and adoption of LOQTORZI in NPC
- •Clinical readouts for tagmokitug program expected in 2026
Medium-Term (6-18 months)
- •Clinical readouts for casdozokitug program expected in 2026
- •Potential expansion of LOQTORZI indications or market access
- •Advancement of other pipeline assets into later-stage clinical trials
Long-Term (18+ months)
- •LOQTORZI establishing market leadership in the NPC treatment landscape
- •Multiple proprietary oncology products approved and commercialized
- •Transformation into a leading focused oncology biopharma company
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for CHRS?
- ✓
Consistent double-digit (or higher) quarter-over-quarter growth in LOQTORZI revenue.
- ✓
Positive clinical data readouts for tagmokitug and casdozokitug in 2026, advancing them to next phases.
- ✓
Evidence of effective cost management leading to a reduced cash burn rate.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Coherus Oncology Inc Makes Money
Coherus Oncology Inc. is a biopharmaceutical company that develops and commercializes innovative therapies, primarily focusing on oncology. Its current flagship product, LOQTORZI, is a first-in-class drug approved for treating nasopharyngeal carcinoma (NPC), a type of head and neck cancer. Coherus generates revenue by selling LOQTORZI to healthcare providers and also by advancing a pipeline of novel oncology treatments through clinical trials, with the long-term goal of bringing additional proprietary drugs to market to address significant unmet medical needs in cancer care. The business model involves substantial upfront research and development investment with the aim of high-margin product sales upon regulatory approval.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Coherus Oncology Inc (CHRS)?
As of April 9, 2026, Coherus Oncology Inc has a DVR Score of 7.1 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Coherus Oncology Inc?
Coherus Oncology Inc's market capitalization is approximately $250.3M..
What is the risk level for CHRS stock?
Our analysis rates Coherus Oncology Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of CHRS?
Coherus Oncology Inc currently has a price-to-earnings (P/E) ratio of -1.4. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Coherus Oncology Inc's revenue growing?
Coherus Oncology Inc has reported revenue growth of 59.7%. The company is showing strong top-line momentum.
Is CHRS stock profitable?
Coherus Oncology Inc has a profit margin of -434.2%. The company is currently unprofitable.
How often is the CHRS DVR analysis updated?
Our AI-powered analysis of Coherus Oncology Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 9, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CHRS (Coherus Oncology Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.